Unicycive Therapeutics, Inc.

UNCY Healthcare Biotechnology

Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022. In the quarter to June 2026, EPS grew 88.5% and free cash flow grew 9.77%, each against the same quarter a year earlier.

3.36 0.23 −6.41%
Market cap
$100.0M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
n/a
Altman Z
−10.79
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
71.32 63.55 48.96 50.29
Total non-current assets
0.71 0.86 0.17 0.32
Total Assets
72.03 64.41 49.14 50.61
Total current liabilities
18.70 26.49 18.94 13.13
Total non-current liabilities
0.06 0.22 — —
Total liabilities
18.76 26.70 18.94 13.13
Common Equity (Total)
53.27 37.70 30.20 37.48
Shareholders Equity (Total)
53.27 37.70 30.20 37.48

Show all line items

In millions of $ except per-share values · columns are period end dates